GIPR

Hong Kong-based biotech Insilico Medicine has nominated ISM1354, a GIPR antagonist designed with its generative AI platform, as a preclinical development candidate for obesity and related metabolic disorders. It is the latest example of artificial intelligence compressing early drug discovery, and observers see it as a test of whether AI-designed molecules can advance into serious clinical pipelines for weight-loss treatment.

Insilico Medicine has nominated ISM1354, a GIPR antagonist designed using its artificial intelligence drug discovery platform, as a preclinical candidate for obesity and related metabolic diseases. The company says the molecule was generated and optimised end-to-end with generative AI tools. It adds to a growing slate of AI-discovered drugs moving toward clinical development, as pharmaceutical firms race to apply machine learning to the booming obesity treatment market.